Theralase Technologies (Theralase Technologies) Debt-to-EBITDA : -0.11 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Theralase Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Theralase Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.07 Mil. Theralase Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.22 Mil. Theralase Technologies's annualized EBITDA for the quarter that ended in Dec. 2023 was $-2.72 Mil. Theralase Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.11.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Theralase Technologies's Debt-to-EBITDA or its related term are showing as below:

TLTFF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.12 Med: -0.02 Max: -0.01
Current: -0.12

During the past 13 years, the highest Debt-to-EBITDA Ratio of Theralase Technologies was -0.01. The lowest was -0.12. And the median was -0.02.

TLTFF's Debt-to-EBITDA is ranked worse than
100% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.245 vs TLTFF: -0.12

Theralase Technologies Debt-to-EBITDA Historical Data

The historical data trend for Theralase Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies Debt-to-EBITDA Chart

Theralase Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.02

-0.01

-0.10

-0.09

Theralase Technologies Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.09	-0.15	-0.09	-0.10	-0.11

Competitive Comparison of Theralase Technologies's Debt-to-EBITDA

For the Medical Devices subindustry, Theralase Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's Debt-to-EBITDA falls into.

Theralase Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Theralase Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.069	+	0.219)	/	-3.171
	=	-0.09

Theralase Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.069	+	0.219)	/	-2.72
	=	-0.11

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Theralase Technologies (OTCPK:TLTFF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Theralase Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies (Theralase Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (OTCPK:TLTFF) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

TLT:Canada

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.